VCAN and cancer: The potential for inhibiting VCAN to enhance the effects of drugs such as cisplatin, gemcitabine and epirubicin shows that VCAN could potentially serve as a biomarker to identify patients who are at a higher risk of developing cancer or who may respond better to drug therapies.